Last close ₹1,655.00down ₹23.00 (1.37%)BSE ₹1,656.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,678.00.
52-week range of traded prices to 23 Oct 2026
₹1,597.00Low, 2 Apr 2026₹2,195.00High, 23 Oct 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,65,141 Cr27th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 26.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 3.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.09%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.5%
- NIMNet interest margin. Net interest income ÷ the average assets that earn interest × 100 × 12 ÷ the months in the period, a rate per year; given only where the balance sheets at the start and at the end of the period are both held; not given for an insurer. For the year to Mar 2026.
- 8.00%
- Cost of fundsCost of funds. Interest paid ÷ the average of what the company pays interest on × 100 × 12 ÷ the months in the period, a rate per year; given only where the balance sheets at the start and at the end of the period are both held; not given for an insurer. For the year to Mar 2026.
- 7.21%
- Credit costCredit cost. What was set aside for loans that may not be repaid ÷ average loans given × 100 × 12 ÷ the months in the period, a rate per year; given only where the balance sheets at the start and at the end of the period are both held; not given for an insurer. For the year to Mar 2026.
- 2.09%
- ROAReturn on assets. Profit after tax ÷ average total assets × 100 × 12 ÷ the months in the period, a rate per year; given only where the balance sheets at the start and at the end of the period are both held; not given for an insurer. It equals net interest income + other income − operating expenses − provisions + exceptional items − tax + the lines below tax, each on the same base. For the year to Mar 2026.
- 2.79%
- LeverageAssets per rupee of net worth. Average total assets ÷ average net worth: rupees of assets for each rupee of net worth; given only where the balance sheets at the start and at the end of the period are both held; not given for an insurer. For the year to Mar 2026.
- 5.24times net worth
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 10,35,02057.1% delivered
Bajaj Finserv share news and announcements
764 announcements, routine notices left out, newest first. Page 8 of 16.
Jul 2021
21 Jul · Disclosure
21 Jul · Business
21 Jul · Board meeting
Jun 2021
May 2021
Apr 2021
28 Apr · Disclosure
28 Apr · Board meeting
28 Apr · Board meeting
Mar 2021
Feb 2021
Jan 2021
20 Jan · Board meeting
Dec 2020
Nov 2020
Oct 2020
21 Oct · Board meeting
Sep 2020
30 Sep · Legal
Exchange has sought clarification from Bajaj Finserv Limited with respect to announcement dated 22-Sep-2020, regarding " Bajaj Finserv Limited has informed the Exchange regarding 'We are sending herewith a copy of the first product offering from its Health-Tech venture, Bajaj Finserv Health Limited, a wholly-owned subsidiary of the Company". On basis of above the Company is required to clarify following: 1. Cost of acquisition or the price at which the shares are acquired;2. Nature of consideration - whether cash consideration or share swap and details of the same;The response of the Company is awaited.16 Sep · Disclosure
Aug 2020